Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
Drug toxicity: Drug–Drug Interaction01:30

Drug toxicity: Drug–Drug Interaction

Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
Drug Toxicity: Risk factors01:24

Drug Toxicity: Risk factors

Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Patient Satisfaction and Supportive Care Pathways in a German Head and Neck Tumor Center: A Prospective Cross-Sectional Study.

Healthcare (Basel, Switzerland)·2026
Same author

Accidental Exposure to Poisonous Houseplants: An Analysis of Cases Reported to Poison Information Centers.

Deutsches Arzteblatt international·2026
Same author

Association of red blood cell transfusions with periventricular leukomalacia in very preterm infants.

Vox sanguinis·2026
Same author

Prognostic factors and cervical lymph node management in tongue squamous cell carcinoma: a retrospective cohort study.

Clinical oral investigations·2026
Same author

Bronchoscopy Identifies Bacterial Airway Colonization and Comorbidities in Preschool Children With Refractory Respiratory Symptoms: A Retrospective Study.

Pediatric pulmonology·2026
Same author

Alternaria Sensitization and Allergy in Children and Adolescents: A Retrospective Diagnostic Study.

Journal of asthma and allergy·2026

Related Experiment Video

Updated: Jun 3, 2026

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform
06:21

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform

Published on: May 10, 2024

Glycine affects valproate hepatotoxicity.

Lara Junius1, Thomas Brune, Michael Deters

  • 1Department of Paediatrics, Otto von Guericke University of Magdeburg, 39120 Magdeburg, Germany. 2.adresse@web.de

Research Communications in Molecular Pathology and Pharmacology
|April 8, 2011
PubMed
Summary

Glycine protects human liver cells from valproate toxicity. This study shows glycine reduces valproate-induced liver damage in Hep G2 cells, suggesting a potential therapeutic role.

More Related Videos

Manufacturing and Using Piggy-back Multibarrel Electrodes for In vivo Pharmacological Manipulations of Neural Responses
06:52

Manufacturing and Using Piggy-back Multibarrel Electrodes for In vivo Pharmacological Manipulations of Neural Responses

Published on: January 18, 2013

Related Experiment Videos

Last Updated: Jun 3, 2026

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform
06:21

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform

Published on: May 10, 2024

Manufacturing and Using Piggy-back Multibarrel Electrodes for In vivo Pharmacological Manipulations of Neural Responses
06:52

Manufacturing and Using Piggy-back Multibarrel Electrodes for In vivo Pharmacological Manipulations of Neural Responses

Published on: January 18, 2013

Area of Science:

  • Hepatology
  • Pharmacology
  • Toxicology

Background:

  • Valproate is a common anticonvulsant.
  • Valproate can cause rare but severe liver toxicity (hepatotoxicity).
  • The exact mechanism of valproate-induced hepatotoxicity is unclear.

Purpose of the Study:

  • To investigate the potential hepatoprotective effect of glycine against valproate-induced toxicity in human liver cells.
  • To assess valproate toxicity in Hep G2 cells with and without glycine co-administration.
  • To evaluate cell viability and histomorphological changes.

Main Methods:

  • Human hepatoma (Hep G2) cells were cultured in monolayers.
  • Cells were treated with varying concentrations of valproate (1-4 mM) alone and in combination with glycine (12 mmol/l).
  • Cytotoxicity was assessed using neutral red uptake, enzyme release (glutamate dehydrogenase), and histomorphological evaluation.

Main Results:

  • Glycine significantly increased the IC50 value of valproate, indicating reduced cytotoxicity.
  • Glycine decreased the release of glutamate dehydrogenase, a marker of cell membrane damage.
  • Histomorphological analysis showed reduced nuclear deformation and improved cell adherence in cells treated with valproate and glycine.

Conclusions:

  • Glycine demonstrates a hepatoprotective effect against valproate-induced toxicity in human liver cells (Hep G2) in vitro.
  • These findings suggest glycine may mitigate valproate-related liver injury.
  • A non-specific hepatoprotective role for glycine in vitro is proposed.